The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers.

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

Researchers have uncovered critical mechanisms linked to metabolic insufficiencies that underlie plasmacytoid dendritic cell suppression after infection.

The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

In developing effective treatments for most autoimmune diseases, selectively targeting autoimmune B cells is preferred to nonselective B-cell depletion. Petar Lenert and colleagues have developed ...